Facebook Facebook Share

Annwen Jones, Chief Executive

Annwen-Jones-Chief-executive-Target-Ovarian-Cancer-smallAnnwen has extensive experience of leadership, management and campaigning in the non-profit sector, having served previously as Chief Executive of the Juvenile Diabetes Research Foundation and as a trustee of the Association of Medical Research Charities in the UK. Annwen is Vice-Chair of the World Ovarian Cancer Coalition and a co-founder of World Ovarian Cancer Day. She has also served on the Steering Committee for ENGAGe, the European Network of Gynaecological Cancer Advocacy Groups (2014-2016).

Annwen was appointed by NHS England to the National Cancer Drugs Panel in 2014 and currently sits on several clinical trial steering committees, including the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). A highly experienced leader, Annwen also holds a Master of Business Administration degree from Henley Business School.


Alexandra Holden, Director of Communications

Alexandra Holden

Alex joined Target Ovarian Cancer in 2012 and is responsible for brand, PR and digital communications. She has over 20 years’ experience from across the voluntary and corporate sector, with a background in both internal and external communications in the UK, Scandinavia and Australia. Previous organisations have included Bupa, Virgin Media, Mencap, Westpac Bank and GE. Alex has been a trustee for the Twins and Multiple Birth Association (Tamba), a director of Conewood Children’s Centre, a member of NCT’s Voluntary Income Advisory Group and is a member of the Women in PR network.

Alex Horsup, Director of Finance and Corporate Services

Alexandra Horsup

Alex is a CIMA qualified accountant with a diploma in charity accounting from the Cass Business School. She joined Target Ovarian Cancer in 2017, having worked in the charity sector at a senior level for 16 years, covering finance, governance, HR, IT and premises management, most recently as Director of Finance at Young Minds. Prior to that she has worked in both social services and in health. Alex is a trustee of the Mary Ward Centre and was previously Vice Chair of Governors at a nursery school.

Katherine Pinder, Deputy Director of Services

Katherine Pinder

Katherine joined Target Ovarian Cancer in 2014. She is responsible for leading on the support and information programme for women with ovarian cancer, including our information guides, face to face events and most recently launching a nurse-led support line. Kath has over 12 years’ experience running support programmes in the charity sector, and was previously at the British Lung Foundation where she led a team on projects to improve earlier diagnosis, self-management and support for people living with lung disease. Kath has also completed a sabbatical in Borneo with Raleigh International delivering sustainable development projects.

Rebecca Rennison, Director of Public Affairs and Services

Rebecca Rennison

Rebecca joined Target Ovarian Cancer in 2015. Rebecca has over ten years’ policy and campaigns experience. She worked for several national disability charities, including the National Autistic Society and Leonard Cheshire Disability, before making the move to the health sector. Rebecca has experience of running successful national campaigns, influencing government and public body policy, delivering both quantitative and qualitative research, supporting people to advocate for change and building relationships with ministers and other senior stakeholders.

Susan Booth M.InstF.Dip, Director of Fundraising

Susan Booth

Susan joined Target Ovarian Cancer in 2014. She has been instrumental in developing a strong fundraising team that has increased annual income from £1.3m to over £1.8m. With over 16 years’ experience of leading charity fundraising garnered in a wide range of charities from Teenage Cancer Trust to local hospices to the RSPCA and RNLI, Susan is a dedicated senior leader who has the strategic vision and specialised skills to help Target Ovarian Cancer secure the funds needed to transform the future for women with ovarian cancer.